The disclosure provides compositions and methods related to treating, ameliorating, and preventing asthma, and in particular steroid resistant or refractory severe asthma, with an anti-CD6 antibody, itolizumab, or an antigen binding portion thereof, alone or in combination with other agents useful in treating asthma.